Contineum Therapeutics stockholders elect three Class II directors at 2026 annual meeting

Contineum Therapeutics, Inc.

Three Class II directors elected: Evert Schimmelpennink, Lori M. Lyons-Williams, and Diego Miralles, M.D.
Broker non-votes of 6,133,812 shares on each director election.
Ratification of Ernst & Young LLP as independent auditor for FY 2026: 28,021,047 votes for, 16,104 against.
Record date April 27, 2026; 32,723,877 shares of Class A common stock outstanding and entitled to vote.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.